|
| Press Releases |
|
 |
|
| Monday, March 7, 2022 |
|
|
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma |
| Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A. more info >> |
|
| Friday, March 4, 2022 |
|
|
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (BAN2401). more info >> |
|
| Friday, February 25, 2022 |
|
|
Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma |
| Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA. more info >> |
|
| Tuesday, February 1, 2022 |
|
|
Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021 |
| Eisai Co., Ltd. announced today that it was selected as the winner of the Tokyo Governor Prize for Corporate Governance of the Year 2021, which is an award program organized by the Japan Association of Corporate Directors (JACD). more info >> |
|
| Monday, January 31, 2022 |
|
|
Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma |
| This marks the first approval for LENVIMA which will be used in combination with KEYTRUDA for advanced RCC in Asia. more info >> |
|
| Friday, January 28, 2022 |
|
|
Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglected Tropical Diseases |
| Eisai Co., Ltd. announced today that its CEO Haruo Naito participated in the online event entitled "100% COMMITTED to End NTDs" celebrating the 10th anniversary of the London Declaration, an international public-private partnership to eliminate neglected tropical diseases (NTDs), on January 27, 2022. more info >> |
|
|
Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM |
| Biogen Inc. and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer's disease, including details of the study's goal for diverse enrollment and primary endpoint. more info >> |
|
| Thursday, January 20, 2022 |
|
|
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma |
| Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the publication of results from the Phase 3 Study 309/KEYNOTE-775 trial in the January 19, 2022 edition of the New England Journal of Medicine. more info >> |
|
| Wednesday, January 19, 2022 |
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time |
| Eisai Co., Ltd. announced today that it has been listed in the 2022 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >> |
|
|
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study |
| Eisai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has enrolled the first subject in the phase II/III study (Tau NexGen study). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Cropmate Berhad IPO Oversubscribed by 84.88 Times 
Nov 27, 2024 18:00 HKT/SGT
|
|
|
Quranium Launches QSafe Wallet with Core Layer (L1) Testnet: The Uncrackable Solution for Blockchain Security
Nov 27, 2024 17:20 HKT/SGT
|
|
|
Survey: New Opportunities in Cross-border E-commerce
Nov 27, 2024 17:11 HKT/SGT
|
|
|
Step Into the World of Jean-Michel Basquiat
Nov 27, 2024 17:00 HKT/SGT
|
|
|
Indonesia's "Yayasan Kota Kita Surakarta" Receives Recognition from UNAOC-BMW Group's Intercultural Innovation Hub
Nov 27, 2024 17:00 HKT/SGT
|
|
|
Quranium Node Pre-sale Unveiled: Be Part of the Quantum-Uncrackable Revolution
Nov 27, 2024 17:00 HKT/SGT
|
|
|
EdgePoint Infrastructure Inks Strategic Partnership with CelcomDigi to expand connectivity in Malaysia at TowerXchange Meet Up Asia 2024
Nov 27, 2024 16:50 HKT/SGT
|
|
|
Q2 Metals Significantly Expands the Cisco Lithium Property in James Bay, Quebec, Canada
Nov 27, 2024 16:30 HKT/SGT
|
|
|
SF Holding successfully listed in Hong Kong
Nov 27, 2024 16:19 HKT/SGT
|
|
|
Expert Systems Announces FY25 Interim Results
Nov 27, 2024 14:58 HKT/SGT
|
|
|
Kingworld-Longde Life and Health Industrial Park Grand Opening
Nov 27, 2024 14:48 HKT/SGT
|
|
|
Swire Coca-Cola Hong Kong Leverages SAP S/4HANA and SAP Services to Drive Digital Transformation
Nov 27, 2024 14:10 HKT/SGT
|
|
|
Ching Lee Holdings (3728.HK) Reports Significant Growth in Interim Results for 2024
Nov 27, 2024 14:00 HKT/SGT
|
|
|
Genetec maintains stable and profitable performance on a lower Q1FY2025 revenue
Nov 27, 2024 10:00 HKT/SGT
|
|
|
RichTech Digital Berhad Signs Underwriting Agreement with KAF Investment Bank Berhad
Nov 27, 2024 10:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
